Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

Source : https://www.nice.org.uk/guidance/gid-ta10582/documents/html-content-2

The Appraisal Committee has prepared a Final Appraisal Document (FAD) on trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies and submitted it to NICE. The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors.